Integra LifeSciences Holdings Corporation Closes $1.5 Billion Credit Facility

December 7, 2016

S&C advised Integra LifeSciences Holdings Corporation in amending and restating its existing credit agreement. The amendment and restatement revised the company's existing credit facility to provide significant additional flexibility to conduct acquisitions, remove certain financial covenants and extend the maturity of its credit facilities. Integra LifeSciences also upsized its credit facility from $1.1 billion to $1.5 billion, consisting of a $1 billion revolving line of credit and a $500 million term loan A facility, with the option to increase the aggregate size of the credit facility by at least $250 million.

Integra LifeSciences is a world leader in medical technology, offering innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies.

The S&C team was led by Ari Blaut, along with Moritz Raepple. Spencer Simon advised on intellectual property matters. Rebecca Coccaro advised on labor and employment matters.